Changes in the Tear Film With Scleral Contact Lens Wear for Keratoconic Eyes

Sponsor
University of Waterloo (Other)
Overall Status
Completed
CT.gov ID
NCT02806921
Collaborator
Bausch & Lomb Incorporated (Industry)
13
2
18.5

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate changes in the level of inflammatory mediators in the tear film of scleral contact lens wearers in a keratoconic population.

Condition or Disease Intervention/Treatment Phase
  • Device: ZenLens
N/A

Detailed Description

Scleral contact lenses are rigid gas permeable lenses designed to rest on the sclera while vaulting over the cornea with a fluid reservoir. The use of scleral contact lenses has become the current standard of practice as a nonsurgical management of corneal ectasia and ocular surface diseases. Cases have been recently presented of scleral lens wearers exhibiting adverse corneal findings and conjunctival injection from lens wear. These findings are likely associated with the mechanical and hypoxic effects due to poor fitting characteristics at the limbal area. Tear film analysis detecting changes in the levels of proteinases and cytokines have helped researchers gain a better understanding of the pathophysiology of complications in soft contact lenses wearers, dry eye, and keratoconus. Ultimately, this study will provide insights in relating scleral lens fitting characteristics and corneal and limbal physiological responses.

Study Design

Study Type:
Interventional
Actual Enrollment :
13 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Protease and Cytokine Composition in Post Lens Tear Reservoir of Scleral Lenses for Keratoconic Eyes
Actual Study Start Date :
Aug 1, 2016
Actual Primary Completion Date :
Jan 30, 2018
Actual Study Completion Date :
Feb 15, 2018

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: ZenLens with Low limbal clearance

Scleral contact lens designed to provide approximately 25 microns of limbal clearance.

Device: ZenLens
The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.

Active Comparator: ZenLens with High limbal clearance

Scleral contact lens designed to provide approximately 80 microns of limbal clearance.

Device: ZenLens
The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.

Outcome Measures

Primary Outcome Measures

  1. Tear Protein [2 weeks of lens wear with daily schedule of 6-8 hours.]

    To measure the level proteases and cytokines in each of the samples using Meso Scale Discovery system (MSD-ECL).

Secondary Outcome Measures

  1. Comfort [2 weeks of lens wear with daily schedule of 6-8 hours.]

    Participants will be asked to rate their ocular comfort, dryness, burning and vision with the contact lenses.

  2. Bulbar and limbal hyperemia [2 weeks of lens wear with daily schedule of 6-8 hours.]

    The eyes of the participants will be imaged using the Keratograph® 5.

  3. Corneal thickness [2 weeks of lens wear with daily schedule of 6-8 hours.]

    Their corneal thickness will be measured with the Visante OCT.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Had been diagnosed with keratoconus in at least one eye.

  • Is at least 18 years of age and has full legal capacity to volunteer.

  • Has read and understood the information consent letter.

  • Is willing and able to follow instructions and maintain the appointment schedule.

Exclusion Criteria:
  • Is using any topical medications that will affect ocular health.

  • Has any ocular pathology or severe insufficiency of lacrimal secretion (severe dry eyes) that would affect the wearing of contact lenses.

  • Has persistent, clinically significant corneal or conjunctival staining using sodium fluorescein dye.

  • Has any clinically significant lid or conjunctival abnormalities and active neovascularization.

  • Is aphakic.

  • Has undergone any corneal surgery.

  • Is participating in any other type of eye related clinical or research study.

  • Has any known allergies or sensitivity to the diagnostic pharmaceuticals or products, such as fluorescein, used in this study.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Waterloo
  • Bausch & Lomb Incorporated

Investigators

None specified.

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Luigina Sorbara, Associate Professor, University of Waterloo
ClinicalTrials.gov Identifier:
NCT02806921
Other Study ID Numbers:
  • 14620
First Posted:
Jun 21, 2016
Last Update Posted:
Jun 27, 2019
Last Verified:
Jun 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Luigina Sorbara, Associate Professor, University of Waterloo
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 27, 2019